Medicare could save more than $3B annually by using Mark Cuban’s new online generic drug company — study – Endpoints News

Medicare could save more than $3B annually by using Mark Cuban’s new online generic drug company — study – Endpoints News

Pfizer is experiencing an uptick in litigation related to its covid-19 blockbuster and therapeutic treatment, with the latest suit coming from Massachusetts-based Enanta Pharmaceuticals.

Enanta on Wednesday filed a lawsuit against Pfizer in Massachusetts district court, seeking damages for infringement of a patent it originally filed in July 2020.

Specifically, Enanta claims that Pfizer’s nirmatrelvir, the newly developed half of Paxlovid, violates Enanta’s patent on multiple fronts for its Covid-19 protease inhibitor drug candidate. While Enanta said he doesn’t want to stop the sale, distribution or production of Paxlovid, he also said he wants to be reimbursed with what he calls “fair compensation.”

Read more Endpoints with a free subscription

Unlock this story instantly and join the 144,200+ biopharmaceutical professionals who read Endpoints every day, and it’s free.


Leave a Comment

Your email address will not be published.